Improvement of endothelial function by HMG-CoA reductase inhibitors

Drug News and Perspectives

Volumn 15, Issue 2, 2002, Pages 85-92

  Wassmann, Sven ^a   Nickenig, Georg ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SIMVASTATIN; SUPEROXIDE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANGINA PECTORIS; ANIMAL MODEL; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME INHIBITION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; OXIDATIVE STRESS; RAT; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR ENDOTHELIUM;

EID: 0036237421     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2002.15.2.840047     Document Type: Review

References (65)

1. Vascular endothelium: An integrator of pathophysiologic stimuli in atherosclerosis
2. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress
3. Atherosclerosis - An inflammatory disease
4. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease
5. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction
6. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels
7. Generation of superoxide by purified brain nitric oxide synthase
8. Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries
9. Endothelial function and oxidant stress
10. Phagocytes and oxidative stress
11. Reactive oxygen species, cell signaling, and cell injury
12. Dual role of reactive oxygen species in vascular growth
13. Cell signaling by reactive nitrogen and oxygen species in atherosclerosis
14. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress
15. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats
16. Hypertension-induced end-organ damage: A new transgenic approach to an old problem
17. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts
18. Oxidized thiols markedly amplify the vascular response to balloon injury in rabbits through a redox active metal-dependent pathway
19. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease
20. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells
21. NAD(P)H oxidase: Role in cardiovascular biology and disease
22. A central role for the endothelial NADPH oxidase in atherosclerosis
23. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology
24. Superoxide production and reactive oxygen species signaling by endolhelial nitric-oxide synthase
25. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats
26. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2-imbalance in insulin-resistant rat aorta
27. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process
28. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors
29. Mechanisms underlying endothelial dysfunction in diabetes mellitus
30. Current perspectives on statins
31. A receptor-mediated pathway for cholesterol homeostasis
32. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis
33. Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia
34. Choice of lipid-lowering drugs
35. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
36. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
37. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
38. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
39. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
40. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
41. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)
42. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
43. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kipl)
44. Beneficial effects of statins in coronary artery disease - Beyond lowering cholesterol
45. Upregulation of endothelial nitric oxide svnthase by HMG CoA reductase inhibitors
46. Inhibition of 3-hdroxy-3-methylglutaryl (HMG) CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase
47. HMG-CoA reductase inhibitors improve endothelial dysfunction in nonrmocholeslerolemic hypertension via reduced production of reactive oxygen species
48. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-I gene expression by simvastatin in vascular endothelial cells
49. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells. Involvement of angiotensin AT-receptor expression and racl GTPase
50. Pleiotropic effects of statins: Do they matter?
51. Statins as a newly recognized type of immunomodulator
52. Mechanisms of acute coronary syndromes and the potential role of statins
53. The role of isoprenoids in vascular smooth muscle: Potential benefits of statins unrelated to cholesterol lowering
54. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway
55. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary arter-disease
56. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals
57. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholexterolaemic patients
58. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
59. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
60. Reduction in serum cholesterol with pravastatin improves eudotheliton-dependent coronary vasomotion in patients with hypercholesterolemia
61. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary, artery disease
62. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks
63. Cerivastatin, a hydroxymethylglutaryl coenzyme a reducrase inhibitol; improves endothelial function in elderly diabetic patients within 3 days
64. Rapid effects on vascularfunction after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men
65. Simvastatin preserves coronary endothelial,function in hypercholesterolemia in the absence of lipid lowering